Folitixorin - Isofol

Drug Profile

Folitixorin - Isofol

Alternative Names: 6R-MTHF; [6R] 5,10-methylenetetrahydrofolate; ISO-901; Methylenetetrahydrofolate - Isofol; Modufolin; Modulfolin; MTHF - Isofol

Latest Information Update: 07 Jun 2016

Price : $50

At a glance

  • Originator Merck Eprova
  • Developer Isofol Medical
  • Class 3-ring heterocyclic compounds; Antineoplastics; Chemoprotectants; Chemosensitisers; Folic-acids; Imidazolidines; Pyrimidinones; Small molecules; Tetrahydrofolates
  • Mechanism of Action Antimetabolites; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Colorectal cancer; Folic acid deficiency; Rectal cancer

Most Recent Events

  • 24 May 2016 Isofol Medical plans a phase II/III trial for Colorectal cancer
  • 16 Mar 2016 9192677-Financing info updated
  • 04 Feb 2015 Folitixorin is available for licensing Worldwide as of 04 Feb 2015. http://www.isofol.se/home.aspx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top